Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reaffirmed a Buy rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) and increased the price target from $32 to $45.
December 07, 2023 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer maintains a Buy rating on Rhythm Pharmaceuticals and raises the price target to $45.
The increase in price target by a reputable analyst typically signals a positive outlook on the company's future performance and can lead to increased investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100